Track Your CD4 Count and Viral Load! Use TheBody.com's New Health Tracker!

HIV/AIDS Basics & Prevention

Just Diagnosed

HIV Treatment

Living With HIV

AIDS Policy & Activism

HIV Around the World

Conference Coverage

Trizivir (AZT/3TC/Abacavir)

The Basics | Research

Show Archived (Historical) Articles

Brand Name:	Trizivir
Generic Name:	Zidovudine/ lamivudine/ abacavir, AZT/3TC/ABC
Adult Single Dose:	One tablet containing 300 mg AZT, 150 mg 3TC and 300 mg ABC (twice a day)
Food & Liquid Restrictions:	None
Drug Class:	NRTI

The Basics

An Overview of Trizivir (AZT/3TC/Abacavir) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health
Trizivir (March/April 2009)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
Patient Information About Trizivir (AZT/3TC/Abacavir) (PDF) (March 2009)
From GlaxoSmithKline
Trizivir (Zidovudine + Lamivudine + Abacavir) (September 26, 2008)
To read PDF, click here
From AIDS InfoNet
Trizivir (AZT + Epivir + Ziagen) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
Trizivir (AZT/3TC/Abacavir) (August 15, 2006)
From AIDS Treatment Data Network

Research

The End of the Line for an Induction-Maintenance Approach to HIV Treatment Involving Zidovudine/Lamivudine/Abacavir? (November 14, 2006)
In 8th International Congress on Drug Therapy in HIV Infection
Zidovudine/Lamivudine/Abacavir May Be Appropriate for Some Treatment-Naive Patients With Low-Baseline Viral Loads (September 28, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Incidence of Zidovudine-Associated Anemia May Be Lower Than Initially Thought -- Particularly With Fixed-Dose Combinations (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
Trizivir Preferred Over Continued HAART in HIV-Infected Patients (March/April 2002)
TRIZAL study results; highlights from ICAAC 2002.
In Body Positive, from Body Positive
Comparison of the Metabolic Disorders and Clinical Lipodystrophy 48 Weeks After Switching From HAART to Trizivir Versus Continued HAART (TRIZAL: AZL30002) (October 26, 2001)
In 3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO
Protease Inhibitor Class-Sparing Maintenance Therapy With Abacavir (ABC) + Lamivudine (3TC) + Zidovudine (ZDV) in Patients With Long-Term Suppression of HIV-1 RNA (February 2000)
From Seattle Treatment Education Project

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.